REVIEW ARTICLE ON LEUCAENA LEUCOCEPHALA AS ONE OF THE MIRACLE TIMBER TREES

Leucaena leucocephala trees are commonly known as White Lead tree. It is native to Southern Mexico and Northern Central America and spread across many tropical and sub-tropical locations. It has multipurpose uses, such as generation of firewood, timber, greens, fodder, and green manure, as well as to provide shade and control soil erosion. It has been used for medicinal purposes because of possessing multiple pharmacological properties. Studies have shown the presence of various secondary metabolites such as alkaloid, cardiac glycosides, tannins, flavonoids, saponins, and glycosides in this species. In traditional medicine, it is used to control stomach ache and as contraception and abortifacient. In the present study, the global distribution, taxonomy, chemical composition, pharmacological activities, and potential uses of Leucaena leucocephalaare discussed

Essential oil loaded pectin/chitosan nanoparticles preparation and optimization: via Box-Behnken design against MCF-7 breast cancer cell lines

In the continuous search for effective cancer treatments, we here report a novel anticancer nanoparticulate system composed of jasmine oil (JO), an essential oil with proven anticancer activity and pectin/chitosan composite nanoparticles (Pec/CS NPs) as encapsulating materials to overcome JO's solubility and sensitivity problems using a green ionotropic gelation method. Pec/CS/JO NPs were formulated using Box–Behnken design (BBD) to estimate the interactions and effects of studied formulation variables on particle size, zeta potential and encapsulation efficiency to develop an optimized Pec/CS nanoformulation. The nano-encapsulation system preserved the consistency of total phenolic contents in JO and amended its thermal stability by 1.64 fold. The antioxidant potency of JO was enhanced after encapsulation by 96.28%. Consequently, the cytotoxic activity of bare Pec/CS NPs, pure JO and encapsulated JO in Pec/CS NPs against (MCF-7) breast cancer cells and (L-929) normal cells was evaluated using MTT assay. Encapsulated JO was more potent than pure JO with ≈13 fold improvement in anticancer activity, whereas the cell viability of normal cells wasn't affected but was rather enhanced when treated with Pec/CS NPs

REVIEW ARTICLE ON LEUCAENA LEUCOCEPHALA AS ONE OF THE MIRACLE TIMBER TREES

Leucaena leucocephala trees are commonly known as White Lead tree. It is native to Southern Mexico and Northern Central America and spread across many tropical and sub-tropical locations. It has multipurpose uses, such as generation of firewood, timber, greens, fodder, and green manure, as well as to provide shade and control soil erosion. It has been used for medicinal purposes because of possessing multiple pharmacological properties. Studies have shown the presence of various secondary metabolites such as alkaloid, cardiac glycosides, tannins, flavonoids, saponins, and glycosides in this species. In traditional medicine, it is used to control stomach ache and as contraception and abortifacient. In the present study, the global distribution, taxonomy, chemical composition, pharmacological activities, and potential uses of Leucaena leucocephalaare discussed

Essential oil loaded pectin/chitosan nanoparticles preparation and optimization <i>via</i> Box–Behnken design against MCF-7 breast cancer cell lines

Pec/CS/JO formulated nanocomposite showed a 13-fold increase in potency against cancer cells, whereas cell viability of normal cells wasn't affected.</p

Versatile Nanoparticulate Systems as a Prosperous Platform for Targeted Nose-Brain Drug Delivery

The intranasal route has proven to be a reliable and promising route for delivering therapeutics to the central nervous system (CNS), averting the blood-brain barrier (BBB) and avoiding extensive first-pass metabolism of some drugs, with minimal systemic exposure. This is considered to be the main problem associated with other routes of drug delivery such as oral, parenteral, and transdermal, among other administration methods. The intranasal route maximizes drug bioavailability, particularly those susceptible to enzymatic degradation such as peptides and proteins. This review will stipulate an overview of the intranasal route as a channel for drug delivery, including its benefits and drawbacks, as well as different mechanisms of CNS drug targeting using nanoparticulate drug delivery systems devices; it also focuses on pharmaceutical dosage forms such as drops, sprays, or gels via the nasal route comprising different polymers, absorption promoters, CNS ligands, and permeation enhancers

Molecular characterization of multidrug-resistant Gram-negative pathogens in three tertiary hospitals in Cairo, Egypt

AbstractHigh rates of antimicrobial resistance (AMR) among Gram-negative pathogens (GNP) have been reported in Egypt. Antimicrobial surveillance and identifying the genetic basis of AMR provide important information to optimize patient care. In this study, we aimed to identify the beta-lactam resistance phenotypes and genotypes of multidrug-resistant (MDR) non-repetitive GNP from 3 tertiary hospitals in Egypt. WZe studied 495 non-repetitive MDR Gram-negative isolates from patients with complicated intra-abdominal infections (cIAI), complicated urinary tract infection (cUTI), and lower respiratory tract infection (LRTI), collected as part of the “Study for Monitoring Antimicrobial Resistance Trends” (SMART) conducted in 3 tertiary hospitals in Cairo, Egypt, from 2015 to 2016. Identification and susceptibility testing of GNP to antimicrobials were tested in each hospital laboratory and confirmed in a reference laboratory (International Health Management Associates (IHMA), Inc., Schaumburg, IL, USA). Molecular identification of extended-spectrum beta-lactamases (ESΒLs), AmpC, and carbapenem resistance genes was conducted in IHMA. Among the 495 MDR isolates, Klebsiella pneumoniae (K. pneumoniae) and Escherichia coli (E. coli) were the most common (52.7% and 44.2%). K. pneumoniae was most susceptible to colistin, amikacin, ertapenem, and imipenem (92.7%, 72.7%, 69.3%, and 64%, respectively). E. coli was most susceptible to colistin (100%), amikacin (94.1%), imipenem (90.4%), and ertapenem (83.6%). ESBL was detected in 96.2% and ESBL genotypes included blaCTX-M-15 (70.1%), blaTEM-OSBL (48.5%), blaSHV-OSBL (27.9%), and blaCTX-M-14 (10.7%). AmpC resistance genes were identified in 9.7% of the isolates, dominated by blaCMY-2 (5.7%). Carbapenem resistance genes were detected in 45.3% of the isolates. In K. pneumoniae, blaOXA-48 dominated (40.6%), followed by blaNDM-1 (23.7%) and blaOXA-232 (4.5%). In E. coli, the most frequent genes were blaNDM-5 (9.6%), blaOXA-181 (5.5%), blaOXA-244 (3.7%), and blaNDM-1 (3.7%). blaKPC-2 was identified in 0.4% of isolates. Notably, 32.3% of isolates carried more than one resistance gene. Our findings emphasize the continued need for molecular surveillance of MDR pathogens, implementation of strict infection control measures, and antimicrobial stewardship policies in our hospitals.</jats:p